DaVita
$233.60
▼ -2.71%
−$6.50
NYSE · Healthcare · Medical Care Facilities
· price updated 9h ago
DVA · NYSE · Healthcare · Medical Care Facilities · price updated 9h ago
$233.60
▼ -2.71% · −$6.50 today
AI research · $233.60
Operating record
Capital structure
Valuation
Forward P/E
Price against expected earnings
Favorable · 30% below Sector avg · favorable
15.68x
Price / sales
Value assigned to each sales dollar
Strong · Under 3x annual sales
1.11x
Price / FCF
Price against free cash generation
Strong · Under 20x free cash flow
10.33x
EV / EBITDA
Operating value including debt
Strong · Under 12x operating cash earnings
9.98x
Quality
ROIC
Return earned on invested capital
Reasonable · An 8% to 15% return on capital
12.1%
ROE
Profit generated from shareholder equity
Favorable · Exceptional vs sector peers
81.0%
Debt / equity
Balance-sheet leverage
Rich · Debt is above 1.5x equity
12.61x
Current ratio
Short-term assets against liabilities
Reasonable · Assets still cover near-term liabilities
1.42x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $15.41B | 23.0 | +6.7% | 67 | |
| $10.69B | 18.4 | +23.5% | 78 | |
| $4.88B | 20.3 | +10.3% | 77 | |
| $31.49B | 32.9 | +15.5% | 77 | |
| $1.08T | 41.4 | +47.4% | 76 |
US stock research
DaVita — US core universe (S&P 500 sourced). DVA was -2.7% in the latest available session at $233.60. Its reported market value was $15.41B with a trailing P/E of 23.0. Latest reported revenue was $13.84B, changing +6.7% year over year, with $781.42M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.